You are using an older browser version. Please use a supported version for the best MSN experience.

AbbVie May Not Get All of Allergan for Antitrust Reasons, Argus Analyst Toung Says

Jun.25 -- David Toung, analyst at Argus Research, discusses AbbVie's $63 billion deal for Allergan on "Bloomberg Markets."
image beaconimage beaconimage beacon